Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug
sbtlneet / Pixabay

Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug

According to a story from BioSpace, Oncotelic, Inc., recently announced the publication of a study in the Journal of Clinical Research in Pediatrics. This study appears to back up the therapeutic…

Continue Reading Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug

Study Shows Tysabri Reduces Risk of Cognitive Decline for Pediatric-Onset Multiple Sclerosis Patients

The Gap Tysabri is a therapy that has shown efficacy for reducing disease activity in patients diagnosed with pediatric-onset multiple sclerosis (POMS). Previous investigations have indicated that up to 58%…

Continue Reading Study Shows Tysabri Reduces Risk of Cognitive Decline for Pediatric-Onset Multiple Sclerosis Patients
The Society for Participatory Medicine Conference: A College Student’s Perspective
crystal710 / Pixabay

The Society for Participatory Medicine Conference: A College Student’s Perspective

As a second year pre-medical student at Northeastern University, my desire to become a healthcare professional flourishes every day. An advantage of being a student who is just beginning to…

Continue Reading The Society for Participatory Medicine Conference: A College Student’s Perspective

Phase 1 Trial for Niemann-Pick Disease Type C Has Completed Enrollment

Niemann-Pick disease type C (NPC) is a rare disease caused by a defected NPC protein. In a healthy individual, this protein helps the body process cholesterol. Those diagnosed with NPC experience…

Continue Reading Phase 1 Trial for Niemann-Pick Disease Type C Has Completed Enrollment
FDA Announces Label Expansion for Treprostinil to treat Pulmonary Arterial Hypertension
jarmoluk / Pixabay

FDA Announces Label Expansion for Treprostinil to treat Pulmonary Arterial Hypertension

According to a story from MDMag, the US Food and Drug Administration (FDA) has recently approved a label expansion for the drug treprostinil (marketed as Orentiram). This update to the…

Continue Reading FDA Announces Label Expansion for Treprostinil to treat Pulmonary Arterial Hypertension
New Prime Editing Has The Potential to Search and Replace up to 89% of Genetic Defects
source: pixabay.com

New Prime Editing Has The Potential to Search and Replace up to 89% of Genetic Defects

  CNN recently covered a story in the publication Nature about a paper explaining base editing (or prime editing). The researchers who created the technology set forth the process of using base…

Continue Reading New Prime Editing Has The Potential to Search and Replace up to 89% of Genetic Defects
11 Year Old Aims to Spread Awareness about Primary Pulmonary Hypertension, a Rare Disease That has Ravaged Her Family
Free-Photos / Pixabay

11 Year Old Aims to Spread Awareness about Primary Pulmonary Hypertension, a Rare Disease That has Ravaged Her Family

According to a story from the Borehamwood & Elstree Times, the family of 11 year old girl Sivan Hermon is plagued by a rare disease: primary pulmonary hypertension. As the…

Continue Reading 11 Year Old Aims to Spread Awareness about Primary Pulmonary Hypertension, a Rare Disease That has Ravaged Her Family
Close Menu